09.02.2017
B.R.A.I.N. Biotechnology Research And Information Network AG DE0005203947
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Free Float of BRAIN share successfully increased
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Miscellaneous
B.R.A.I.N. Biotechnology Research And Information Network AG: Free Float of
BRAIN share successfully increased
09.02.2017 / 11:04
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Free Float of BRAIN share successfully increased
Zwingenberg, February 9, 2017: Yesterday evening, B.R.A.I.N. Biotechnology
Research and Information Network AG ("BRAIN AG", ISIN DE0005203947 / WKN
520394) was informed that after the end of the one-year lock-up period, MIG
Fonds, as existing shareholders of the company, sold its entire stake of
2,528,389 shares to more than 20 institutional investors. The placement
took place outside the stock market as part of an accelerated book-building
process. The transaction, which was oversubscribed several times, was
accompanied by ODDO SEYDLER BANK AG and Baader Bank AG. The free float of
BRAIN shares increased from 22% to 37%.
Dr Jürgen Eck, CEO of BRAIN AG, is pleased about the strong demand from
investor interest for the BRAIN share: "The MiG funds are early-stage
investors, which provide venture capital for founders and young companies.
They have financially supported the development of BRAIN AG for many years
and have thus also contributed significantly to our success. I would
therefore like to expressly thank you for the excellent and trustworthy
cooperation in recent years. The high demand on the part of the investors
is a further confirmation of our operating business."
"As a result of the placement, the free float of BRAIN share has
significantly increased, which will also improve the tradability of the
share for all investors. I am satisfied that based on the high demand from
investors, a successful transaction for the MiG funds could be carried out
as Joint Global Coordinator by the accompanying banks ODDO SEYDLER BANK AG
together with BAADER BANK AG as joint bookrunners", says Frank Goebel,
Member of the Management Board of BRAIN AG.
About BRAIN
BRAIN is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN
identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this "Toolbox of Nature" are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars - "BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive - collaboration business
with industrial partners. The second pillar "BioIndustrial" comprises the
development and commercialisation of BRAIN's own products and active
product components. Further information is available at www.brain-
biotech.de/en
Contact:
B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
Tel.: +49-6251-9331-16
Fax: +49-6251-9331-11
E-Mail: [email protected]
www.brain-biotech.de
Disclaimer
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. There are numerous factors
which could influence the future performance by and future developments at
BRAIN AG and the BRAIN group of companies. Such factors include, but are
not limited to, changes in the general economic and competitive
environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations,
in particular with respect to tax laws and regulations, and other factors.
BRAIN AG does not undertake any obligation to update or revise any forward-
looking statements.
---------------------------------------------------------------------------
09.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
543277 09.02.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
B.R.A.I.N. Biotechnology Research And Information Network AG ISIN: DE0005203947 können Sie bei EQS abrufen
Biotechnologie , 520394 , BNN , XETR:BNN